Choolip & Sciences츌립앤사이언스
291650 · KOSDAQ · ₩291650 · 츌립앤사이언스
₩2,385▼ ₩15 (0.63%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩3.5B | ₩1.1B | ₩243M | ₩358M | ₩269M |
| Cost of sales | ₩1.8B | ₩311M | ₩52M | ₩72M | ₩113M |
| Gross profit | ₩1.7B | ₩772M | ₩191M | ₩287M | ₩156M |
| Operating income | −₩7.8B | −₩7.1B | −₩12B | −₩8.3B | −₩4.1B |
| Net income | −₩8.6B | −₩8.7B | −₩14B | −₩7.1B | −₩3.8B |
| Net income to shareholders | −₩8.6B | −₩8.7B | −₩14B | −₩7.1B | −₩3.8B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩41B | ₩32B | ₩33B | ₩46B | ₩33B |
| Current assets | ₩26B | ₩19B | ₩25B | ₩38B | ₩25B |
| Cash and equivalents | ₩21B | ₩11B | ₩1.2B | ₩1.2B | ₩1B |
| Total liabilities | ₩13B | ₩6.5B | ₩17B | ₩16B | ₩1.8B |
| Current liabilities | ₩12B | ₩3.9B | ₩15B | ₩2.5B | ₩432M |
| Borrowings | ₩7.3B | ₩1.8B | ₩8.2B | ₩6.8B | — |
| Total equity | ₩28B | ₩25B | ₩15B | ₩29B | ₩31B |
| Shareholders' equity | ₩28B | ₩25B | ₩15B | ₩29B | ₩31B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩9.7B | −₩5.9B | −₩11B | −₩5.8B | −₩3.5B |
| Capital spending | −₩20M | −₩1.1B | −₩297M | −₩309M | −₩7.1B |
| Free cash flow | −₩9.7B | −₩7B | −₩12B | −₩6.1B | −₩11B |
Consolidated where available. Amounts in won.
Also known as: Choolip & Sciences / 츌립앤사이언스 / 291650 / KRX:291650
Source: KRX statistical information